BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30168613)

  • 1. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.
    Kisiel JB; Dukek BA; V S R Kanipakam R; Ghoz HM; Yab TC; Berger CK; Taylor WR; Foote PH; Giama NH; Onyirioha K; Abdallah MA; Burger KN; Slettedahl SW; Mahoney DW; Smyrk TC; Lewis JT; Giakoumopoulos M; Allawi HT; Lidgard GP; Roberts LR; Ahlquist DA
    Hepatology; 2019 Mar; 69(3):1180-1192. PubMed ID: 30168613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma.
    Qin Y; Wu CW; Taylor WR; Sawas T; Burger KN; Mahoney DW; Sun Z; Yab TC; Lidgard GP; Allawi HT; Buttar NS; Smyrk TC; Iyer PG; Katzka DA; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2019 Dec; 25(24):7396-7404. PubMed ID: 31527170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
    Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
    Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma.
    Chalasani NP; Ramasubramanian TS; Bhattacharya A; Olson MC; Edwards V DK; Roberts LR; Kisiel JB; Reddy KR; Lidgard GP; Johnson SC; Bruinsma JJ
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2597-2605.e4. PubMed ID: 32889146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.
    Anderson BW; Suh YS; Choi B; Lee HJ; Yab TC; Taylor WR; Dukek BA; Berger CK; Cao X; Foote PH; Devens ME; Boardman LA; Kisiel JB; Mahoney DW; Slettedahl SW; Allawi HT; Lidgard GP; Smyrk TC; Yang HK; Ahlquist DA
    Clin Cancer Res; 2018 Nov; 24(22):5724-5734. PubMed ID: 29844130
    [No Abstract]   [Full Text] [Related]  

  • 7. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
    Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
    Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
    Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
    Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
    Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
    Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HepaClear, a blood-based panel combining novel methylated CpG sites and protein markers, for the detection of early-stage hepatocellular carcinoma.
    Bai Y; Xu J; Li D; Zhang X; Chen D; Xie F; Huang L; Yu X; Zhao H; Zhang Y
    Clin Epigenetics; 2023 Jun; 15(1):99. PubMed ID: 37308980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma.
    Yang JD; Ghoz H; Aboelsoud MM; Taylor WR; Yab TC; Berger CK; Cao X; Foote PH; Giama NH; Barr Fritcher EG; Mahoney DW; Moser CD; Smyrk TC; Kipp BR; Gores GJ; Roberts LR; Kisiel JB
    Hepatol Commun; 2021 Aug; 5(8):1448-1459. PubMed ID: 34430788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma.
    Huang ZH; Hu Y; Hua D; Wu YY; Song MX; Cheng ZH
    Exp Mol Pathol; 2011 Dec; 91(3):702-7. PubMed ID: 21884695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
    Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
    Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase.
    Yang JD; Dai J; Singal AG; Gopal P; Addissie BD; Nguyen MH; Befeler AS; Reddy KR; Schwartz M; Harnois DM; Yamada H; Gores GJ; Feng Z; Marrero JA; Roberts LR
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1085-1092. PubMed ID: 28258053
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of endometrial cancer using tampon-based collection and methylated DNA markers.
    Bakkum-Gamez JN; Sherman ME; Slettedahl SW; Mahoney DW; Lemens MA; Laughlin-Tommaso SK; Hopkins MR; VanOosten A; Shridhar V; Staub JK; Cao X; Foote PH; Clarke MA; Burger KN; Berger CK; O'Connell MC; Doering KA; Podratz KC; DeStephano CC; Schoolmeester JK; Kerr SE; Wentzensen N; Taylor WR; Kisiel JB
    Gynecol Oncol; 2023 Jul; 174():11-20. PubMed ID: 37141817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.
    Zhou J; Yu L; Gao X; Hu J; Wang J; Dai Z; Wang JF; Zhang Z; Lu S; Huang X; Wang Z; Qiu S; Wang X; Yang G; Sun H; Tang Z; Wu Y; Zhu H; Fan J
    J Clin Oncol; 2011 Dec; 29(36):4781-8. PubMed ID: 22105822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma.
    Shi M; Chen MS; Sekar K; Tan CK; Ooi LL; Hui KM
    Eur J Cancer; 2014 Mar; 50(5):928-36. PubMed ID: 24332572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma.
    Zhu HT; Liu RB; Liang YY; Hasan AME; Wang HY; Shao Q; Zhang ZC; Wang J; He CY; Wang F; Shao JY
    Liver Int; 2017 Jun; 37(6):888-896. PubMed ID: 28061012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.